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Given potential values of induced pluripotent stem (iPS) cells in basic biomedical research and regenerative medicine, it
is important to understand how these cells regulate their genome stability in response to environmental toxins and
carcinogens. The present study characterized the effect of Cr(VI), a well-known genotoxic agent and environmental
carcinogen, on major molecular components of DNA damage response pathways in human iPS cells. We compared the
effect of Cr(VI) on human iPS cells with two established cell lines, Tera-1 (teratoma origin) and BEAS-2B (lung epithelial
origin). We also studied the effect of hydrogen peroxide and doxorubicin on modulating DNA damage responses in
these cell types. We demonstrated that ATM and p53 phosphorylation is differentially regulated in human iPS cells
compared with Tera-1 and BEAS-2B cells after exposure to various genotoxic agents. Moreover, we observed that
inhibition of CK2, but not p38, promotes phosphorylation of p53S392 in iPS cells. Combined, our data reveal some unique
features of DNA damage responses in human iPS cells.
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Induced pluripotent stem (iPS) cells are derived from som-
atic cells through genetic re-programming. Simultaneous
ectopic expression of key transcription factors such as
OCT4, SOX2, KLF4 and c-MYC can reprogram human
somatic cells to pluripotent stem cells capable of differenti-
ation into a variety of cell types [1]. Human iPS cells thus
represent a valuable resource for the development of
in vitro models for human diseases and have great poten-
tials in regenerative medicine [2]. Recent studies have
shown that human iPS cells also offer a valuable alternative
to human embryonic stem cells for drug development [3],
as well as for in vitro expansion and differentiation into
cells of the hematopoietic lineage [4,5]. It is well known
that cells undergoing in vitro expansion are constantly
exposed to a variety of environmental insults including
genotoxic agents and oxidative stress. Given the great* Correspondence: zengwnxian@hotmail.com; wei.dai@nyumc.org
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reproduction in any medium, provided the orpotential of iPS cells, it is imperative to understand the
characteristics of these cells, especially regarding their gen-
omic stability after exposure to environmental genotoxic
agents.
Chromium (VI) compounds are well established environ-
mental carcinogens that produce genotoxic effects leading
to human cancers [6-9]. Chromium (VI) generates reactive
oxygen species (ROS) that induce DNA damage, which is
thought to trigger DNA damage responses in somatic cells
[6-8]. Although some studies have been carried out with
an emphasis on toxic and carcinogenic effects of Cr(VI)
compounds on somatic cells [7,8], its effect on human iPS
cells remains largely unknown. In fact, very limited studies
have been conducted on DNA damage responses caused
by genotoxic agents in either embryonic stem cells or iPS
cells. Cr(VI) has been shown to inhibit differentiation of
murine embryonic stem cells [10]. A strong DNA damage
response induced by γ-irradiation has been demonstrated
in human iPS cells [11]. Given the unique chromatin struc-
ture of iPS cells, it is likely these cells may respond to
DNA damage differently after challenge with genotoxic
agents including Cr(VI) compared with those cells of the
somatic origin.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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events including auto-phosphorylation of ATM and phos-
phorylation of histone H2AX and p53 [12,13]. Extensive
research in the past has identified amino acid residues in
these proteins that are characteristic of DNA damage
responses [13-17]. They include ATMS1981, p53S15, p53S20,
p53S392, and H2AXS139 [13-17]. In the current study, we
evaluated the effect of Cr(VI) on expression and/or activa-
tion of several key molecular components mediating DNA
damage responses in human iPS cells and compared it with
those of transformed cells from the somatic origin (Tera-1
and BEAS-2B). As additional controls, we also exposed
these cells to H2O2 and doxorubicin (Dox), two well stud-
ied genotoxic agents. We found that human iPS cells
responded differently to Cr(VI) compared with Tera-1 and
BEAS-2B cells in terms of activation of DNA damage
response pathway. In addition, we observed that iPS cells,
Tera-1 and BEAS-2B exhibited differential responses after
H2O2 or Dox treatment. Our findings indicate that iPS
cells have some unique features to Cr(VI) and other
genotoxic agents that can be explored for potential
drug developments.Experimental procedures
Cell lines and cell culture
Human induced pluripotent stem cells were derived from
human amniotic fluid-derived cells (hAFDCs) via retrovirus-
mediated expression of four transcription factors (OCT4/
SOX2/KLF4/C-MYC). Human iPS cells were cultured in 6-
cm tissue culture dishes coated with matrix (Invitrogen,
USA) in a feeder-free culture conditions using Essential 8™
medium. Human iPSCs grown on feeder-dependent culture
conditions (Mitomycin C treated murine embryonic fibro-
blasts) were maintained in DMEM-F12 (Invitrogen, USA)
medium which was supplemented with 20% KSR, 10 ng/mL
bFGF, 2 mM GlutaMAX™-I, 0.1 mM MEM Non-Essential
Amino Acids Solution, 1 × β-mercaptoethanol. Cells were
passed every 5–6 days after trypsinization. Mitomycin C
treated murine embryonic fibroblasts (MEFs) were prepared
as feeder cells. Tera-1 cells obtained from American Type
Culture Collection (ATCC) were cultured in McCoy’s 5A
medium supplemented with 10% fetal bovine serum (FBS).
BEAS-2B cells obtained from ATCC were cultured in
DMEM supplemented with 10% FBS.Antibodies
Antibodies to p53, NANOG and SOX2 (for flow cytome-
try) were purchased from Santa-Cruz Biotechnology. Anti-
bodies to OCT4, SOX2 (for Western blot), ATM,
phospho-ATMS1981 (p-ATMS1981), p-p53S15, p-p53S20, γ-
H2AX, p-p53S392, p-p38, p38, PARP-1, α-tubulin, β-actin
were purchased from Cell Signaling Technology.Fluorescence microscopy
Human iPS cells were fixed in 4% paraformaldehyde
(PFA) and washed with PBS containing 5% BSA and
0.4% Triton X-100. These cells were subsequently incu-
bated with antibodies against OCT4 at 37°C for 1 h
followed by washing three times with PBS with Tween.
Cells were then incubated with a secondary antibody
conjugated with Alexa Fluor 555 at 37°C for 45 min
followed by wash three times with PBS with Tween.
After brief staining with Hoechst, cells were examined
under a fluorescence microscope.Flow cytometry analysis
Human iPS cells were disaggregated by 0.5 mM EDTA,
washed with PBS, and then treated with 4% PFA and
0.4% Triton X-100 for 30 min. After wash twice with
cold PBS containing 0.5% fetal bovine serum, cells were
incubated with an anti-human NANOG or SOX2 anti-
body for 30 min at 4°C. Subsequently, these cells were
stained with a second antibody IgG conjugated with
Alexa Fluor555 for 30 min. Isotype control IgG was
used as control. The fluorescence-labeled cells were an-
alyzed with flow cytometry.Differentiation of iPS cells
Human iPS cells were maintained in Essential 8TM medium
(Life Technologies). OP-9 cells were cultured in the MEMα
medium containing 20% FCS. The iPS cells were induced
to differentiate into embryonic stem cell sacs (ES-sacs) as
described [18]. Briefly, the small clumps of human iPS cells
were transferred onto OP-9 cells and cultured in a differen-
tiation medium (IMDM supplemented with 10 μl/ml ITS
100× stock solution, 2 mM L-glutamine, 0.45 μM MTG,
50 μg/ml ascorbic acid, 15% FBS and 20 ng/ml recombin-
ant human VEGF), which was refreshed every 3 days. On
days 14 to 15 of culture, ES-sacs emerged. Representative
images of ES-sacs were captured under microscope. Hu-
man iPS cells were induced to differentiate toward the
neural lineage was carried out using STEMdiff™ Neural In-
duction Medium according to the manufacturer’s protocol
(Stem Cell Technologies).Western blot
Human iPS cells treated with appropriate chemicals for
various times were washed twice with ice-cold PBS and
lysed in 310 μL RIPA buffer supplemented with protease
and phosphatase inhibitors. Cell lysates were centrifuged
by at 12,000 g for 15 min at 4°C. Equal amounts of cell
lysates (20 μg) were mixed with 6× SDS loading buffer,
heated at 100°C for 5 min, and analyzed by SDS-PAGE
followed by Western blotting.
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Characterization of human iPS cells
Human iPS cells were obtained from amniotic fluid-derived
cells after ectopic expression of four stem cell transcription
factors (OCT4, SOX2, KLF4 and c-MYC) via the retroviral
expression system. Microscopic examinations revealed that
these cells exhibited a stem cell-like morphology and
expressed abundant OCT4 and SOX2 (Figure 1A and B).
Further characterization via flow cytometry indicated that
these cells were also highly positive for NANOG and
SOX2. We further examined these for their capacity for
differentiation. Through incubation in a medium optimal
for differentiation, we observed that these cells were cap-
able of differentiating into cells with morphologic charac-
teristics of neural cells or embryonic stem cell sacs (ES
sacs) (Figure 1D). Combined, these results indicate that iPS
cells under study bear essential characteristics of stem cells.
Dose-dependent responses of human iPS and Tera-1 cells
to Cr(VI)
To study whether iPS cells were capable of responding to
Cr(VI), we treated iPS cells, as well as Tera-1 cells as con-
trol, with the compound at various concentrations for 24 h.
Western blot analysis revealed that p53 protein level
displayed a slight increase after treatment with Cr(VI) in
iPS cells (Figure 2A). We did not detect any significant in-
duction of p-ATMS1981 (p-ATM thereafter) signals in hu-
man iPS cells (Figure 2A). In Tera-1 cells, p-ATM was
induced by 10 μM Cr(VI), peaking at 25 μM (Figure 2B). In
iPS cells, a relatively high basal level of γH2AX was present
in untreated cells, which was not further increased after Cr
(IV) treatment. In contrast, no basal level of γH2AX was
detectable in Tera-1 cells and it was strongly induced by Cr
(VI) at concentrations higher than 25 μM, which coincided
with ATM phosphorylation/activation (Figure 2B). Phos-
phorylation of p53 on both S15 and S20 also exhibited a
differential response to Cr(VI) treatment between iPS and
Tera-1 cells. In iPS cells, p53 phosphorylation on S20 was
not easily detectable whereas its phosphorylation on S15
was somewhat inducible. On the other hand, both S20 and
S15 phosporylation in Tera-1 cells was strongly induced
and S20 phosphorylation exhibited a dose-dependent
increase after Cr(VI) treatment (Figure 2). The pattern of
phosphorylation closely followed that of p-ATM signals.
Combined, these data suggests that iPS cells are more
resistant to Cr(VI)-induced DNA damage or that the DNA
damage response pathway is suppressed in iPS cells. Intri-
guingly, expression of OCT4 in Tera-1 cells, but not in iPS
cells, was suppressed by Cr(VI) (Figure 2A and B).
Time-dependent response of human iPS, Tera-1, and
BEAS-2B cells to Cr(VI)
We next determined the kinetics of phosphorylation/
activation of various components in the DNA damage-response pathway. We treated iPS and Tera-1 cells with
10 μM Cr(VI) as this concentration elicited a minimal
response of apoptosis while it activated ATM and p53
phosphorylation in Tera-1 cells (Figure 2B). We also
treated BEAS-2B cells with Cr(VI) as an additional som-
atic cell control. In these experiments, iPS cells were
cultured under feeder-free cultural conditions as op-
posed to the feeder-dependent condition in the previous
studies so as to eliminate any potential interference of
signals from the feeder cells.
There was a clear time-dependent increase in the p53
protein level in iPS cells and Tera-1 cells after Cr(VI)
treatment (Figure 3A and B). A longer Cr(VI) treatment
caused a decline of p53 in iPS cells. Interestingly, the
p53 level in BEAS-2B was not significantly modulated
during the treatment period (Figure 3C). The p-ATM
level in iPS cells exhibited a biphasic pattern of induc-
tion after Cr(VI) treatment. It was slightly induced at
about 1 h after treatment and then declined below the
basal level until it increased again after cells were treated
for more than 24 h (Figure 3A). The γH2AX signal was
closely associated with the second phase of ATM phos-
phorylation in iPS cells. The p-ATM level in Tera-1 cells
was only significantly elevated 24 h post Cr(VI) treat-
ment, which was also correlated with the γH2AX signal
(Figure 3B). Despite the non-detectable level of p-ATM
in BEAS-2B cells, the γH2AX signal was increased in a
manner similar to that in either iPS or Tera-1 cells.
Phosphorylation of p53 in three cells types was quite dif-
ferent. While the level of p-p53S15 in iPS cells did not
show significant changes over time after Cr(VI) treatment,
it was strongly induced in Tera-1 and BEAS-2B cells and
its induction was time-dependent (Figure 3A-C). However,
the p-p53S15 signal increased beyond 48 h in Tera-1 cells
whereas it peaked at about 4 h post Cr(VI) treatment. In
both iPS and Tera-1 cells, the level of p-p53S20 was un-
detectable before and after Cr(VI) treatments (Figure 3A
and B). In contrast, p-p53S20 signal exhibited a time-
dependent increase post treatment in BEAS-2B cells
(Figure 3C). The phosphorylation level of p-p53S392, an-
other important phosphorylation site in response to
genotoxic stress [13], was distinctive among these three
cell types. There were no detectable basal levels of p-
p53S392 in iPS cells and Tera-1 cells (Figure 3A and B).
However, it was inducible in Tera-1 cells after Cr(VI)
treatment. There was a high basal level of p-p53S392 in
BEAS-2B cells, which could not be further induced by
exposure to Cr(VI).
Time-dependent response of human iPS cells, Tera-1, and
BEAS-2B cells to H2O2
One of the main mechanisms for Cr(VI)-induced DNA
damage responses is the generation of reactive oxygen spe-
cies (ROS) [6-9]. We next examined the effect of H2O2 on
Figure 1 Characterization of iPS cells. (A) General morphology of iPS cells under study. (B) Human iPS cells were cultured on chamber slides,
fixed and stained with either a control IgG or antibodies to SOX2 and OCT4. DNA was stained with Hoechst. Representative images are shown.
(C) Human iPS cells were fixed and stained with either IgG or antibodies to NANOG and SOX2. Cells were then processed for analysis by flow
cytometry. Experiments were repeated for at least three times. (D) Human iPS cells were cultured in a differentiation medium as described in
Experimental procedures. Representative images of embryonic stem cell sacs (ES-sacs) and neural differentiation are shown.
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sponses in iPS, Tera-1 and BEAS-2B cells. We observed
that different cell types responded to H2O2 in a manner
similar to that of Cr(VI) with regard to p53 induction and
activation (Figure 4). The total p53 level was slightly in-
duced in iPS cells and was below the pretreatment levelafter 24 h treatment (Figure 4A). Whereas p53 was grad-
ually induced in Tera-1 cells it was not significantly
changed in BEAS-2B cells (Figure 4B and C). The p-ATM
level in iPS cells treated with H2O2 displayed a biophasic
pattern similar to that of Cr(VI) treatment (Figure 4A). In
Tera-1 cells, however, p-ATM was induced most strongly
Figure 2 Dose-dependent responses of human iPS and Tera-1 cells to Cr(VI). (A) Human iPS cells were cultured with feeder cells as
described in Experimental procedures and treated with Cr(VI) at various concentrations for 24 h. Whole cell lysates were then collected for
Western blot analyses with various antibodies as indicated. (B) Tera-1 cells were cultured as indicated in Experimental procedures and treated
with Cr(VI) for 24 h. Equal amounts of cell lysates were blotted with antibodies as indicated.
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ferent from that of Cr(VI) treated Tera-1 cells, which only
showed significant elevation of p-ATM at 24 h and 48 h
time points (Figure 3B). In BEAS-2B cells, the p-ATM level
was only slightly elevated over time after H2O2 treatment
(Figure 4C), which is similar to the response to Cr(VI)
(Figure 3C). The level of γH2AX in three cell types
responded very differently to H2O2 compared with that in
cells treated with Cr(VI). In iPS cells, it was strongly in-
duced and the induction was time-dependent (Figure 4A).
Surprisingly, we did not observe any induction of γH2AX
in Tera-1 and BEASE-2B cells after H2O2 treatment
(Figure 4B and C). This is in sharp contrast with the re-
sponses of these cells to Cr(VI), which was strongly in-
duced at 48 h after Cr(VI) treatments (Figure 4B and C).
In iPS cells, the level of p-p53S15 was significantly increased
in a time-dependent fashion, peaking at 8 h of treatment
(Figure 4A). Interestingly, H2O2 did not significantly induce
p-p53S15 in either Tera-1 or BEAS-2B cells. Therefore,
H2O2 behaves differently in induction of p-p53
S15 com-
pared with that of Cr(VI). Similar to Cr(VI), H2O2 did not
induced any p-p53S20 (compare Figures 3A and 4A). How-
ever, the level of p-p53S20 in Tera-1 cells was elevated in re-
sponse to H2O2 treatments (Figure 4B). This was in
contrast to the response to Cr(VI), which showed noincrease (Figure 3B). In Tera-1 cells, p-p53S392 levels were
rapidly induced by H2O2 and remained elevated throughout
the time course, which was different from the time-
dependent increase shown in Cr(VI) treatments (Figure 3B
with Figure 4B). In BEAS-2B cells, however, the kinetics of
p-p53S392 level after H2O2 treatment was similar to that of
Cr(VI) (Figure 3C with Figure 4C).
Time-dependent response of human iPS cells, Tera-1, and
BEAS-2B cells to Dox
Given that doxorubicin (Dox) is capable of inducing
double strand breaks [19,20], we further analyzed DNA
damage responses in three different cell types after treat-
ment with this chemical compound. Again, we observed
that general patterns of total p53 levels in response to
Dox were similar to those induced by either Cr(VI) or
H2O2. A steady increase of p53 was observed in both
iPS and Tera-1 cells whereas it was largely unchanged in
BEAS-2B cells (Figure 5). In contrast to Cr(VI) and
H2O2, Dox induced p-ATM in a time-dependent fashion
in iPS cells (Figure 5A). The level of p-ATM in Tera-1
and BEAS-2B cells after Dox treatment was similar to
that of H2O2 (Figure 5B). It rapidly increased, peaking at
about 4 h post treatment followed by a gradual decline
to the pretreatment level (Figure 5B and C). Gamma
Figure 3 Time-dependent responses of human iPS cells, Tera-1, and BEAS2B cells to Cr(VI). (A) Human iPS cells were cultured under the
feeder-free condition as described in Experimental procedures and treated with 10 μM Cr(VI) for various times as indicated. The whole cell lysates
were collected and equal amounts of cell lysates were blotted with various antibodies as indicated. (B) Tera-1 cells were treated and analyzed as
shown in A. (C) BEAS2B cells were treated and analyzed as shown in A.
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duced after extended treatment with Dox (Figure 5A and
C). Intriguingly, γH2AX signals in Tera-1 cells were transi-
ently induced at about 4 h post treatment (Figure 5B). Dif-
ferent from Cr(VI), Dox was capable of inducing p-p53S15
in iPS cells (Figure 5A). On the other hand, Dox induced
p-p53S15 only after 24 h of treatment (Figure 5B), which is
very different from that in cells treated with Cr(VI) or
H2O2. Phosphorylation of p53 on S20 was only strongly in-
duced by Dox in BEAS-2B cells whereas phosphorylation
on S392 was induced in both iPS and Tera-1 cells, but not
in BEAS-2B cells. Table 1 summarizes the time-dependent
responses of the three cell lines to three different types of
genotoxic agents.
Roles of p38 and CK2 on p53S392 phosphorylation
The striking difference in p53S392 phosphorylation be-
tween three cell types in response to different stimuli
prompted us to further explore on the potential kinases
that phosphorylate this residue in these cells. Previous
studies have shown that the p38 MAP kinase and casein
kinase 2 (CK2) are the main kinases that phosphorylate
p53S392 [21-23]. We examined whether these two kinases
are responsible for the observed differential phosphoryl-
ation of this residue. As shown in Figure 6A (lanes 1–8),
p38 was not activated by these genotoxic agents as indi-
cated by the p-p38 level. The specific p38 inhibitor
SB203580 had no effect on the phosphorylation of p53S392
induced by H2O2 or Dox in iPS or Tera-1 cells. In BEAS-
2B cells, p38 was only activated by Cr(VI). However, thehigh basal level of p-p53S392 in BEAS-2B cells, which was
not induced by the genotoxic agents, was not affected by
p38 inhibition. HeLa cells treated with 500 mM NaCl were
used here as a positive control for p38 activation (lanes 9–
11). These data indicate that p38 is unlikely the kinase that
phosphorylated p53S392 in these cells before and after ex-
posure to these genotoxic agents.
To determine whether CK2 was responsible for p53S392
phosphorylation, we first treated cell with LiCl, which sig-
nificantly inhibits CK2 [24]. As shown in Figure 6 (lanes
1–8, right panels), LiCl treatment led to increased levels of
p53S392 phosphorylation with or without treatment with
genotoxic agents in iPS cells. In contrast, LiCl had a limited
effect on p53S392 phosphorylation in Tera-1 cells. The high
basal level of p-p53S392 in BEAS-2B cells was not affected
by LiCl treatment either. Since the elevated p-p53S392 level
induced by LiCl in iPS cells appears to correlate with the
increased level of total p53, we normalized the level of total
p53 to see if the difference in the p-p53S392 level still exists.
As shown in Figure 6B, the elevated p-p53S392 level re-
mains after normalization of total p53 among treatments,
indicating that LiCl indeed promotes the phosphorylation
of p53S392 in iPS cells.
We next treated cells with 4,5,6,7-tetrabromobenzi-
midazole (abbreviated as TBBz), a specific inhibitor of
CK2 [25], to determine whether phosphorylation of
p53S392 is at least partly mediated by CK2 in iPS cells. As
shown in Figure 6C, TBBz treatment significantly en-
hanced phosphorylation of p53S392 in iPS cells, which is
similar to the effect observed after LiCl treatment in these
Figure 4 Time-dependent responses of human iPS, Tera-1, and BEAS2B cells to H2O2. (A) Human iPS cells were cultured under the feeder-
free condition as described in Experimental procedures and treated with 100 μM H2O2 for the indicated time periods (h). The whole cell lysates
were collected and equal amounts of lysates were blotted with antibodies to various cellular components as indicated. (B) Tera-1 cells were
treated and analyzed as described in A. (C) BEAS-2B cells were treated and analyzed as described in A.
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inhibition promotes phosphorylation of p53S392 in iPS
cells before and after exposure to genotoxic agents.
Discussion
The current study surveys the activation of several key ele-
ments of DNA damage response pathways in human iPS,
Tera-1 cells, and BEAS-2B cells after treatment with Cr
(VI), a well documented genotoxic agent. We also com-
pared the responses of those cells to other DNA damagingFigure 5 Time-dependent responses of iPS, Tera-1, and BEAS2B cells
free condition as described in Experimental procedures and treated with 2
and equal amounts of lysates were blotted with various antibodies as indic
(C) BEAS-2B cells were treated and analyzed as described in A.agents including H2O2 and Dox. Our results indicate that
iPS cells possess a rather distinct pattern of responses com-
pared with established cell lines. While Cr(VI) induces
ATM phosphorylation in a unique biphasic fashion and in-
creases the level of γH2AX after prolonged treatments in
iPS cells it is largely unable to elicit phosphorylation of p53
on S15, S20, and S392 in these cells (Figure 3A and
Table 1). In contrast, the level of p-p53S15 is easily indu-
cible by H2O2 and Dox and p53
S392 is strongly induced by
Dox in iPS cells (Figures 4A, and 5A). The p-p53S20 levelto Doxorubicin. (A) Human iPS cells were cultured under the feeder-
50 nM Dox for the indicated times. Whole cell lysates were collected
ated. (B) Tera-1 cells were treated and analyzed as described in A.
Table 1 Time-dependent responses of human iPS, Tera-1, and BEAS-2B cells after treatment with Cr(VI), H2O2, or Dox
Cell type Treatment Total p53 p-ATM γH2AX p-p53S15 p-p53S20 p-p53S392
iPS cells
Cr(VI)
Up early down late Biphasic induction Strongly up late Unchanged Undetectable Undetectable
10 μM
H2O2 Slightly up early and down late Biphasic induction Strongly up late Strongly up early
and down late
Undetectable Slightly up early and down late
100 μM
Dox Slightly up over time Up over time Up late Up early and
down late




Slightly up over time Up late Strongly up late Strongly up overtime Undetectable Strongly up over time
10 μM
H2O2 Slightly up over time Up early and down late Undetectable Unchanged Up over time and
down late
Up early and stays up
100 μM
Dox Significantly up over time Significantly up early
and down late
Strongly up at 8 h
and down late




Unchanged Slightly up over time Strongly up late Up over time Up over time Unchanged
10 μM
H2O2 Unchanged Largely unchanged Undetectable Largely unchanged Largely unchanged Largely unchanged
100 μM




Unchanged up to 24 h




















Figure 6 Roles of p38 and CK2 on p53S392 phosphorylation. (A) Human iPS, Tera-1, or BEAS-2B cells were treated with 10 μM Cr(VI), 100 μM
H2O2, or 250 nM Dox for 4 h with or without pretreatment with 10 μM SB203580 or 10 μM LiCl for one h. HeLa cells treated with 500 mM NaCl was used
as a positive control for p38 activation. Whole cell lysates were collected and equal amounts of cell lysates were blotted with antibodies to various
molecular components as indicated. (B). Different amounts of human iPS cell lysates from experiments described in (A) were used for Western blot to
match (or normalize) the total p53 level as indicated. The p-p53S392 level was detected using the antibody to p-p53S392. (C). Human iPS or BEAS-2B cells
were treated with 10 μM Cr(VI), 100 μM H2O2, or 250 nM Dox for 4 h with or without pretreatment with 10 μM TBBz for one h. The whole cell lysates
were collected and equal amounts of cell lysates were blotted with antibodies to various molecular components as indicated.
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as it fails to respond to any of genotoxic agents under
study. Compared with iPS cells, p53 phosphorylation pat-
terns on these residues in Tera-1 and BEAS-2B cells are
rather different after Cr(VI) treatment. A gross comparison
of the responses of three cell types to these different cat-
egories of genotoxic agents reveals some interesting find-
ings: (i) While p-p53S20 is easily inducible by all three
agents in BEAS-2B cells it is much less responsive, if at all,
in iPS cells and Tera-1 cells; (ii) Although the level of p-
p53S392 in BEAS-2B cells is constitutively elevated it is irre-
sponsive to these genotoxic compounds. On the other
hand, its phosphorylation is elicited in iPS cells and
strongly induced in Tera-1 cells by these compounds.
Phosphorylation of p53 on S15 is known to stabilize
the transcription factor [15,16]. Extensive research in the
past has shown that this residue is the target of multiple
kinases, including ATM and ATR [15,16] whereas S20 is
the target of MAPKAPK2, JNK, CHK2 and Plk3 [15,16].
Consistent with these studies, we also show that ATM is
phosphorylation on S1981 after treatment with various
genotoxic agents, correlating with p53 and γH2AX
phosphorylation. Phosphorylation of p53 on S15 and
S20 is believed to an integral part of the DNA damage
response in vivo [15,16]. The relative resistance of S20
phosphorylation to DNA damaging agents under studyin iPS and Tera-1 cells is intriguing as both types of cells
possess stem cell-like characteristics (Figures 1 and 2)
[1,26]. It is tempting to speculate that stem cells may be
lack of components that lead to p53 phosphorylation on
S20 or that highly activated p53 may not be ideal for
stem cell self-renewal. Supporting this notion, p53 levels
adversely affect reprogramming iPS cells from somatic
cells [27].
It has been shown that phosphorylation of p53 on S392
is mediated by p38, CK2, PKR, and CDK9 [22,28-30] al-
though a recent study suggests that this residue is not a
target of p38 or CK2 but rather of a yet unknown kinase
[23]. Moreover, phosphorylation of this residue appears to
respond to diverse stimuli that induce p53 [23], suggesting
that S392 phosphorylation may play a broad role in the
regulation p53. We have observed that p-p53S392 signals
display rather distinctive profiles in three cell types tested.
Notably, p-p53S392 levels are very low in iPS and Tera-1
cells. While p-p53S392 in Tera-1 cells is highly induced by
all three genotoxic agents it is only significantly induced by
Dox treatment in iPS cells. On the other hand, p-p53S392
levels are high and hardly respond to any type of stimuli
under study. These dramatic differences of p-p53S392 be-
tween these cells reflect a complex regulation of this resi-
due in a cell type-dependent and/or stimulus-dependent
fashion. Our study with specific chemical inhibitors
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http://www.jhoonline.org/content/6/1/71revealed that p38 is not involved in p53S392 phosphoryl-
ation in all three cell types with or without genotoxic in-
sults (Figure 6A). CK2 also seems to be not involved in
p53S392 phosphorylation in Tera-1 and BEAS-2B cells ei-
ther (Figure 6). These results are largely in agreement with
the previous study [23]. Surprisingly, CK2 appears to in-
hibit p53S392 phosphorylation in iPS cells as inhibition of
the enzyme strongly enhances p-p53S392 signals (Figure 6).
This observation is very interesting as previous studies
show that CK2 can promote, rather than inhibit, p53 phos-
phorylation on S392 [31]. Therefore, further investigation
on how CK2 inhibits p53S392 may help to unravel a novel
mechanism of p53 regulation in stem cells after exposure
to genotoxic stress. Of note, in all the three cell types
studied, p53S392 phosphorylation is very closely and
positively correlated with the total p53 level (Figure 6A).
Given that small molecules have been developed for en-
hancing p53 activity for the treatment of various can-
cers [32], our further study of differential responses in
stem cells and somatic cells can lead to the discovery of
new targets for p53 activation.
The main mechanism of Cr(VI)-mediated DNA dam-
age responses is believed to be through the generation of
oxidative stress [6-9]. H2O2 can directly produce oxida-
tive stresses. Dox inhibits the action of topoisomerase II
and also generates oxidative stress, thereby triggering
DNA damage response [19,20]. Despite the overlapping
mechanisms of action of these genotoxic agents, differ-
ential responses as revealed by the current study suggest
that each agent may activate different signaling compo-
nents of the DNA damage response network. Thus, the
effect of Cr(VI) on cellular responses may not be just
limited to the generation of oxidative stresses. Whether
the unique chromatin structures in iPS cells (stem cells)
may contribute to the differential responses remains to
be determined.
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